NEXIGN
Nexign (a part of ICS Holding LLC), a leading Business Support System (BSS) and Internet of Things (IoT) solutions provider, today announced the successful migration of subscribers in all branch offices of the Russian mobile broadband services provider Yota to the Nexign Network Monetisation Suite – a versatile solution for real-time rating, charging and policy control across all network services.
Yota was the first operator to offer its customers communication bundles configurable to minutes and gigabytes, as well as differentiated payment for various types of traffic. Yota’s existing solution did not enable horizontal scaling. The company needed a scalable and flexible instrument for charging and policy control inside the network.
To increase effectiveness of its internal processes, Yota opted for Nexign Network Monetisation Suite, which included solutions like PCRF (Policy and Charging Rules Function), RCAF (RAN congestion awareness function) and UDR (User Data Repository).
As a result, Yota received future-proof solution, which fully met the needs of the mobile operator. Yota reduced the total cost of ownership (TCO) by 10-20% by saving on additional third-party licenses. Use of PCRF function enabled the company to reduce time to market (TTM) by 20% and increase the fault tolerance by 40%, which allows the operator to deliver great customer service and stand out from competition. Nexign’s solution helps Yota provide customer services even in the conditions of congestion.
“The jointed project with Nexign allowed us to launch unique product for the telco market called 'The communications constructor' and maintain high quality of our services while increasing the number of customers. In the past six months the new solution underwent unprecedented stress test. Due to the pandemic, traffic from business apps inside the network has grown 2.5 times,” said Andrey Zhikin, IT Director of Yota .
“This project is the first time when Nexign implemented its solution in a telecom operator that uses a third-party billing system,” said Alexey Vedin, Director of Network Monetisation Products at Nexign . “Integration with Yota’s BSS systems was carried out with no impact on Yota’s customers and without any failures or service interruption. No additional modifications were required on the part of billing or other systems – all the needs of the operator were covered by the capabilities of Nexign’s solution.”
Learn more about Nexign’s products and services here: https://nexign.com/en .
About Nexign
Nexign , a part of Intellectual Computer Systems Holding (https://x-holding.ru/ ) and a leading Business Support System (BSS) and Internet of Things (IoT) solutions provider, has been delivering pragmatic, value-driven, high-performance product solutions since 1992. Nexign has an experience of transformational projects of all scales, and a proven track record of achieving revenue boosts for CSPs through systems consolidation and a faster go-to-market time for new services after modernisation.
Headquartered in St. Petersburg, Nexign employs 1,800 people in offices through Russia, the CIS, the Middle East, Africa, Southeast Asia and LATAM. For more information, please visit the website and follow Nexign on Twitter , Facebook and LinkedIn .
View source version on businesswire.com: https://www.businesswire.com/news/home/20201006006022/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Axelspace: Notice of Signing a Service contract for In-Orbit Demonstration with Pale Blue, Inc.22.12.2025 10:00:00 CET | Press release
Axelspace Corporation (“Axelspace”), a leading microsatellite company committed to making “Space within Your Reach,” has entered into a service agreement with Pale Blue Inc. (“Pale Blue”), a company that develops, manufactures, and sells thrusters (engines) for small satellites, for an in-orbit demonstration, as detailed below. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251219321165/en/ Jun Asakawa, Co-founder & CEO of Pale Blue (left in photo) and Yuya Nakamura, President and CEO of Axelspace Axelspace provides AxelLiner Laboratory (AL Lab), a new service originating from the AxelLiner business that is specialized in in-orbit demonstration of space components. Under this contract, an in-orbit demonstration of a fast-start Hall thruster developed by Pale Blue is scheduled to be conducted in 2027. Nonetheless, conducting in-orbit demonstrations in a short period of time is known to be a significant challenge due to the in
Axelspace Signing Agreement on a Multi-Launch Arrangement and the Launch of New Satellites with Exolaunch22.12.2025 10:00:00 CET | Press release
Axelspace Corporation (“Axelspace”), a leading microsatellite company committed to making “Space within Your Reach,” is pleased to announce a multi-launch agreement (MLA) with Exolaunch, a global launch integrator and leader in launch mission management, satellite integration and satellite deployment technologies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251219038364/en/ The Multi-Launch Agreement will accelerate the growth of Axelspace. In particular, one satellite scheduled for launch under the new Agreement will be used in the AxelLiner business’s in-orbit demonstration service, “AxelLiner Laboratory”. Exolaunch has already secured launches for eight (8) Axelspace’s satellites on the upcoming missions. Axelspace provides AxelLiner Laboratory (AL Lab), a new service originating from the AxelLiner business that is specialized in in-orbit demonstration of space components. Nonetheless, conducting in-orbit demonstration
Zambon Biotech Announces First Patient Dosed in Phase 3b ADIP Clinical Study of IPX203 in Parkinson’s Disease22.12.2025 10:00:00 CET | Press release
Zambon Biotech, a specialized biotech company part of the Zambon group that aims to build a scientifically robust and commercially viable portfolio of innovative patient-oriented drugs through the scouting, acquisition, licensing and development of new molecules, today announced that the first participant with advanced Parkinson’s disease has been enrolled in the European Phase 3b ADIP (IPX203 in Advanced Parkinson’s disease) study, which is planned to evaluate the efficacy and safety of IPX203 versus immediate-release (IR) levodopa/carbidopa (LD/CD) in a regimen which has not yet been the focus of a Phase 3 trial. IPX203 is a novel, oral modified-release formulation of LD/CD designed for the treatment of Parkinson’s disease, the fastest growing neurological condition in the world according to the World Health Organization1. IPX203 contains immediate-release granules and extended-release beads, providing both a rapid onset of action and a longer duration of benefit, sustaining the levo
Pimicotinib Approved as Systemic Treatment in China for Tenosynovial Giant Cell Tumor22.12.2025 09:00:00 CET | Press release
First regulatory approval in the world for pimicotinib based on positive data from global Phase 3 MANEUVER studyIn MANEUVER, pimicotinib significantly improved objective response rate at week 25 (54% vs. 3.2% for placebo), while providing clinically meaningful and statistically significant improvements across all patient-reported outcomesWith longer-term follow-up, 3 out of 4 patients treated with pimicotinib achieved response per RECIST v1.1, and treatment continued to be well-toleratedApproval strengthens Merck’s leadership in rare tumors, with additional ongoing regulatory filings for pimicotinib underway globally Merck, a leading science and technology company, announced today that following Priority Review, the China National Medical Products Administration (NMPA) has approved pimicotinib for the treatment of adult patients with symptomatic tenosynovial giant cell tumor (TGCT) for which surgical resection will potentially cause functional limitation or relatively severe morbidity.
Incyte Japan Announces Approval of Minjuvi® (tafasitamab) in Combination with Rituximab and Lenalidomide for the Treatment of Relapsed or Refractory Follicular Lymphoma22.12.2025 08:44:00 CET | Press release
Incyte Biosciences Japan G.K. today announced approval from Japan's Ministry of Health, Labour and Welfare (MHLW) for Minjuvi® (tafasitamab) in combination with rituximab and lenalidomide for adult patients with relapsed or refractory follicular lymphoma (2L+ FL). “Today's approval of Minjuvi in combination with rituximab and lenalidomide marks a significant milestone as the first dual-targeted CD19 and CD20 immunotherapy combination for relapsed or refractory FL in Japan,” said Yasuyuki Ishida, General Manager, Incyte Biosciences Japan. “By improving progression-free survival, Minjuvi offers a chemotherapy-free option for eligible patients with relapsed or refractory disease. This approval underscores our commitment to bridging critical treatment gaps to patients and families affected by this challenging disease in Japan.” The approval is based on the pivotal Phase 3 inMIND trial, which enrolled 654 adult patients, including patients based in Japan. The study demonstrated that Minjuvi
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom